Diabetes mellitus is an important risk factor for a first cardiovascular event and for worse
outcomes after a cardiovascular event has occurred. This situation might be caused, at least …

Patients with diabetes mellitus (DM) are characterized by enhanced thrombotic risk
attributed to multiple mechanisms including hyperreactive platelets, hypercoagulable status …

OBJECTIVE Patients with diabetes mellitus (DM) and concomitant atherosclerotic
cardiovascular disease (ASCVD) must be on the most effective dose of aspirin to mitigate …

Diabetes mellitus (DM) is a metabolic disorder associated with accelerated atherogenesis
and an increased risk of atherothrombotic complications. Multiple mechanisms contribute to …

A State of the Art lecture titled “Personalizing Antiplatelet Therapy Based on Platelet
Turnover and Metabolic Phenotype” was presented by Bianca Rocca at the International …

Background Vorapaxar is indicated with standard antiplatelet therapy (APT) in patients with
a history of myocardial infarction (MI) or peripheral arterial disease (PAD). Objectives To …

Introduction: Platelets play a key role in pathogenesis of atherothrombosis. Activated
platelets initiate thrombus formation. Antiplatelet therapy (APT) modifies these properties …

The use of the antiplatelet agent aspirin (acetylsalicylic acid) was previously routinely
recommended for the primary prevention of cardiovascular (CV) events in patients with …

Introduction Although the role of aspirin for primary prevention of atherosclerotic
cardiovascular disease (ASCVD) has been disputed, its use in secondary ASCVD …

Objective—Dual-antiplatelet therapy with acetylsalicylic acid and a P2Y12 antagonist, such
as clopidogrel, is the standard of care for acute coronary syndromes. However, the drugs …